Puma Biotechnology targets $192M-$198M NERLYNX revenue for 2025 amid strategic efforts

Stock Information for Puma Biotechnology Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Puma Biotechnology Inc

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Reports First Quarter Financial Results
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients
Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.